Drucker commented: GLP1 [drugs] have given us so many wonderful results, but tackling these very challenging brain disorders has been disappointing There was a hope that we would see some benefit, and we didnt. From the Alzheimers Drug Discovery Foundation (ADDF), Howard Fillit, MD, emphasized that even negative trials move the field forward, pointing to the need to target the broader pathobiology of Alzheimers and to consider preventive or combination approaches informed by biomarker profiles
Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Kber LV, et al
They need more coordination and follow-up
A near-infrared fluorophore for live-cell super-resolution microscopy of cellular proteins
This is key for those thinking about using these medications
Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress